Meldungen zum Thema Health

Folgen
Keine Meldung zum Thema Health mehr verpassen.
Filtern
  • 24.08.2007 – 15:06

    AGA Medical Corporation

    AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II

    Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood ...

  • 22.08.2007 – 15:02

    Roche Pharmaceuticals

    Updated WHO Bird Flu (H5N1) Management Guidance Reinforces Tamiflu as First Line Treatment

    Basel, Switzerland (ots/PRNewswire) - The World Health Organization (WHO) has reinforced that Tamiflu (oseltamivir) is the primary recommended antiviral of choice in managing patients infected with H5N1 in updated guidance published on the WHO website today. Experts believe that a human influenza pandemic is imminent and could be triggered by the highly pathogenic ...

  • 22.08.2007 – 13:06

    SemBioSys, Genetics Inc

    SemBioSys Updates Apo AI Development Program

    Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Confirms Commercial Expression Levels of Apo AI Milano Variant and Clarifies Status of Native Apo AI SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved ...

  • 20.08.2007 – 14:31

    IsoTis OrthoBiologics

    IsoTis Receives FDA Clearance for Accell Family of Products

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...

  • 01.08.2007 – 21:55

    MDS Pharma Services

    MDS Pharma Services Expands Development & Regulatory Services in Europe

    King Of Prussia, Pennsylvania (ots/PRNewswire) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services (DRS) business in Europe. MDS Pharma Services will now offer full-service DRS consulting services to support development of new drugs and ...

  • 01.08.2007 – 08:33

    N.V. Organon

    Eslax(R) (Rocuronium Bromide) Approved in Japan

    Oss, The Netherlands (ots/PRNewswire) - Organon, the human healthcare business unit of Akzo Nobel (Euronext Amsterdam: AKZ), today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved rocuronium bromide, its neuromuscular blocking agent (NMBA) for use during general anesthesia, under the brand name Eslax(R). This drug has a fast onset of action and is one of the most widely used muscle ...

  • 31.07.2007 – 19:08

    AGA Medical Corporation

    AGA Medical Wins Patent Infringement Lawsuit Against Occlutech GmbH

    Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") today announced that it has won its patent infringement lawsuit against Occlutech GmbH, headquartered in Jena, Germany, and DRABO Medizintechnik, located in Cologne, Germany. AGA is the owner of a European patent (EP 0 808 138) registered in Germany (DE 695 34 505) for intravascular occlusion devices ...

  • 31.07.2007 – 03:32

    Takeda Pharmaceutical Company Limited

    Takeda Responds to the FDA Advisory Committee Recommendation

    London (ots/PRNewswire) - Following a joint meeting today of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Takeda Global Research & Development (TGRD) underscores its position that ACTOS(R) (pioglitazone HCl) offers a proven safety profile regarding the risk of cardiovascular disease. "The breadth ...